{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T20:20:05Z","timestamp":1785529205154,"version":"3.56.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Breast Cancer"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The impact of adiposity on the efficacy of endocrine treatment in patients with estrogen receptor positive breast cancer is poorly investigated. Here, we retrospectively investigated in a cohort of 56 patients whether body mass index and\/or mammary adiposity are associated with anti-proliferative response in the neoadjuvant setting. Anti-proliferative response was defined as high Ki67 at baseline (Ki67<jats:sub>bl<\/jats:sub>) and low Ki67 at surgery (Ki67<jats:sub>srg<\/jats:sub>), using the 14% cut-off. Mammary adipocyte size was assessed on hematoxylin and eosin slides from the surgical samples using digital pathology. A higher proportion of tumors with an anti-proliferative response was observed in patients with obesity (54.5%) as compared to patients with normal weight (9.0%) and patients with overweight (40.0%) (<jats:italic>p<\/jats:italic>\u2009=\u20090.031), confirmed by multivariable regression analysis adjusted for baseline Ki67 (OR, obese vs normal weight: 13.76, 95%CI: 1.49\u2013207.63, <jats:italic>p<\/jats:italic>\u2009=\u20090.020). Larger adipocyte diameter was identified as predictor of anti-proliferative response (OR per increase in diameter of 5 \u03bcm for adipocytes distant from the tumor: 2.24, 95%CI: 1.01\u201314.32, <jats:italic>p<\/jats:italic>\u2009=\u20090.046). This study suggests that anti-proliferative response to neoadjuvant letrozole might be more frequent in patients with increased systemic or mammary adiposity.<\/jats:p>","DOI":"10.1038\/s41523-022-00453-7","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T20:14:04Z","timestamp":1659644044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The association between adiposity and anti-proliferative response to neoadjuvant endocrine therapy with letrozole in post-menopausal patients with estrogen receptor positive breast cancer"],"prefix":"10.1038","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1055-7254","authenticated-orcid":false,"given":"Edoardo","family":"Isnaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4353-3619","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxim","family":"De Schepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Leduc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Maetens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8828-8739","authenticated-orcid":false,"given":"Tatjana","family":"Geukens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5700-3574","authenticated-orcid":false,"given":"Karen","family":"Van Baelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2538-7657","authenticated-orcid":false,"given":"Ha-Linh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghizlane","family":"Rouas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Zoppoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6692-2249","authenticated-orcid":false,"given":"Fatima","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5745-9977","authenticated-orcid":false,"given":"Christos","family":"Sotiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Larsimont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2391-5425","authenticated-orcid":false,"given":"Giuseppe","family":"Floris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1202-5873","authenticated-orcid":false,"given":"Elia","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5223-5579","authenticated-orcid":false,"given":"Christine","family":"Desmedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"453_CR1","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1002\/ijc.23943","volume":"124","author":"R Suzuki","year":"2009","unstructured":"Suzuki, R., Orsini, N., Saji, S., Key, T. J. & Wolk, A. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status-A meta-analysis. Int. J. Cancer 124, 698\u2013712 (2009).","journal-title":"Int. J. Cancer"},{"key":"453_CR2","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1093\/jnci\/djab023","volume":"113","author":"AE Lohmann","year":"2021","unstructured":"Lohmann, A. E. et al. Association of obesity with breast cancer outcome in relation to cancer subtypes: a meta-analysis. JNCI: J. Natl Cancer Inst. 113, 1465\u20131475 (2021).","journal-title":"JNCI: J. Natl Cancer Inst."},{"key":"453_CR3","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1002\/cncr.31976","volume":"125","author":"KH Ross","year":"2019","unstructured":"Ross, K. H., Gogineni, K., Subhedar, P. D., Lin, J. Y. & McCullough, L. E. Obesity and cancer treatment efficacy: Existing challenges and opportunities. Cancer 125, 1588\u20131592 (2019).","journal-title":"Cancer"},{"key":"453_CR4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13058-018-1088-6","volume":"21","author":"C Lehu\u00e9d\u00e9","year":"2019","unstructured":"Lehu\u00e9d\u00e9, C. et al. Adipocytes promote breast cancer resistance to chemotherapy, a process amplified by obesity: Role of the major vault protein (MVP). Breast Cancer Res. 21, 7 (2019).","journal-title":"Breast Cancer Res."},{"key":"453_CR5","doi-asserted-by":"publisher","first-page":"2883","DOI":"10.1200\/JCO.19.01771","volume":"38","author":"C Desmedt","year":"2020","unstructured":"Desmedt, C. et al. Differential benefit of adjuvant docetaxel-based chemotherapy in patients with early breast cancer according to baseline body mass index. J. Clin. Oncol. 38, 2883\u20132891 (2020).","journal-title":"J. Clin. Oncol."},{"key":"453_CR6","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/MCO.0000000000000395","volume":"20","author":"MC Gonzalez","year":"2017","unstructured":"Gonzalez, M. C., Correia, M. I. T. D. & Heymsfield, S. B. A requiem for BMI in the clinical setting. Curr. Opin. Clin. Nutr. Metab. Care 20, 314\u2013321 (2017).","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"453_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1158\/1940-6207.CAPR-16-0314","volume":"10","author":"NM Iyengar","year":"2017","unstructured":"Iyengar, N. M. et al. Metabolic obesity, adipose inflammation and elevated breast aromatase in women with normal body mass index. Cancer Prev. Res. 10, 235\u2013243 (2017).","journal-title":"Cancer Prev. Res."},{"key":"453_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/1940-6207.CAPR-10-0381","volume":"4","author":"K Subbaramaiah","year":"2011","unstructured":"Subbaramaiah, K. et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev. Res. 4, 329\u2013346 (2011).","journal-title":"Cancer Prev. Res."},{"key":"453_CR9","doi-asserted-by":"publisher","first-page":"4270","DOI":"10.1200\/JCO.2016.67.4283","volume":"34","author":"NM Iyengar","year":"2016","unstructured":"Iyengar, N. M., Gucalp, A., Dannenberg, A. J. & Hudis, C. A. Obesity and cancer mechanisms: Tumor microenvironment and inflammation. J. Clin. Oncol. 34, 4270\u20134276 (2016).","journal-title":"J. Clin. Oncol."},{"key":"453_CR10","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1158\/0008-5472.CAN-10-3323","volume":"71","author":"B Dirat","year":"2011","unstructured":"Dirat, B. et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res. 71, 2455\u20132465 (2011).","journal-title":"Cancer Res."},{"key":"453_CR11","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso, F. et al. Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30, 1194\u20131220 (2019).","journal-title":"Ann. Oncol."},{"key":"453_CR12","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1001\/jamaoncol.2016.1897","volume":"2","author":"LM Spring","year":"2016","unstructured":"Spring, L. M. et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer a systematic review and meta-Analysis. JAMA Oncol. 2, 1477\u20131486 (2016).","journal-title":"JAMA Oncol."},{"key":"453_CR13","doi-asserted-by":"publisher","first-page":"902","DOI":"10.3390\/cancers13040902","volume":"13","author":"F Lerebours","year":"2021","unstructured":"Lerebours, F., Cabel, L. & Pierga, J.-Y. Neoadjuvant endocrine therapy in breast cancer management: state of the art. Cancers (Basel) 13, 902 (2021).","journal-title":"Cancers (Basel)"},{"key":"453_CR14","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.1245\/s10434-021-10459-3","volume":"28","author":"L Cao","year":"2021","unstructured":"Cao, L. et al. Neoadjuvant endocrine therapy as an alternative to neoadjuvant chemotherapy among hormone receptor-positive breast cancer patients: pathologic and surgical outcomes. Ann. Surg. Oncol. 28, 5730\u20135741 (2021).","journal-title":"Ann. Surg. Oncol."},{"key":"453_CR15","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/jnci\/djk020","volume":"99","author":"M Dowsett","year":"2007","unstructured":"Dowsett, M. et al. Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. J. Natl Cancer Inst. 99, 167\u2013170 (2007).","journal-title":"J. Natl Cancer Inst."},{"key":"453_CR16","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1093\/jnci\/djn309","volume":"100","author":"MJ Ellis","year":"2008","unstructured":"Ellis, M. J. et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J. Natl Cancer Inst. 100, 1380\u20131388 (2008).","journal-title":"J. Natl Cancer Inst."},{"key":"453_CR17","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S1470-2045(20)30458-7","volume":"21","author":"I Smith","year":"2020","unstructured":"Smith, I. et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial. Lancet Oncol. 21, 1443\u20131454 (2020).","journal-title":"Lancet Oncol."},{"key":"453_CR18","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.breast.2013.07.008","volume":"22","author":"PJ Goodwin","year":"2013","unstructured":"Goodwin, P. J. Obesity and endocrine therapy: Host factors and breast cancer outcome. Breast 22, S44\u2013S47 (2013).","journal-title":"Breast"},{"key":"453_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.breast.2011.07.015","volume":"21","author":"M Takada","year":"2012","unstructured":"Takada, M. et al. Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. Breast 21, 40\u201345 (2012).","journal-title":"Breast"},{"key":"453_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10549-022-06525-3","volume":"192","author":"MA Franzoi","year":"2022","unstructured":"Franzoi, M. A., Lambertini, M., Ceppi, M., Bruzzone, M. & de Azambuja, E. Implication of body mass index (BMI) on the biological and clinical effects of endocrine therapy plus abemaciclib as neoadjuvant therapy for early breast cancer patients. Breast Cancer Res. Treat. 192, 457\u2013462 (2022).","journal-title":"Breast Cancer Res. Treat."},{"key":"453_CR21","first-page":"6523","volume":"63","author":"MJ Ellis","year":"2003","unstructured":"Ellis, M. J. et al. Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1\/2 expression status. Cancer Res. 63, 6523\u20136531 (2003).","journal-title":"Cancer Res."},{"key":"453_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.breast.2020.10.004","volume":"54","author":"E Isnaldi","year":"2020","unstructured":"Isnaldi, E. et al. Digital analysis of distant and cancer-associated mammary adipocytes. Breast 54, 179\u2013186 (2020).","journal-title":"Breast"},{"key":"453_CR23","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1200\/JCO.2009.27.2021","volume":"28","author":"I Sestak","year":"2010","unstructured":"Sestak, I. et al. Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: An exploratory analysis from the ATAC trial. J. Clin. Oncol. 28, 3411\u20133415 (2010).","journal-title":"J. Clin. Oncol."},{"key":"453_CR24","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1200\/JCO.2011.40.8666","volume":"30","author":"M Ewertz","year":"2012","unstructured":"Ewertz, M. et al. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1\u201398 trial. J. Clin. Oncol. 30, 3967\u20133975 (2012).","journal-title":"J. Clin. Oncol."},{"key":"453_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/bjc.2013.367","volume":"109","author":"M Gnant","year":"2013","unstructured":"Gnant, M. et al. The predictive impact of body mass index on the efficacy of extended adjuvant endocrine treatment with anastrozole in postmenopausal patients with breast cancer: an analysis of the randomised ABCSG-6a trial. Br. J. Cancer 109, 589\u2013596 (2013).","journal-title":"Br. J. Cancer"},{"key":"453_CR26","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1158\/1940-6207.CAPR-14-0243","volume":"8","author":"NM Iyengar","year":"2015","unstructured":"Iyengar, N. M. et al. Menopause is a determinant of breast adipose inflammation. Cancer Prev. Res. 8, 349\u2013358 (2015).","journal-title":"Cancer Prev. Res."},{"key":"453_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-01308-4","volume":"22","author":"ML Maliniak","year":"2020","unstructured":"Maliniak, M. L. et al. Detection of crown-like structures in breast adipose tissue and clinical outcomes among African-American and White women with breast cancer. Breast Cancer Res 22, 65 (2020).","journal-title":"Breast Cancer Res"},{"key":"453_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-017-0015-9","volume":"3","author":"C Vaysse","year":"2017","unstructured":"Vaysse, C. et al. Inflammation of mammary adipose tissue occurs in overweight and obese patients exhibiting early-stage breast cancer. npj Breast Cancer 3, 19 (2017).","journal-title":"npj Breast Cancer"},{"key":"453_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/endocr\/bqab174","volume":"162","author":"RL Scalzo","year":"2021","unstructured":"Scalzo, R. L. et al. Breast cancer endocrine therapy promotes weight gain with distinct adipose tissue effects in lean and obese female mice. Endocrinology 162, 1\u201319 (2021).","journal-title":"Endocrinology"},{"key":"453_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00232-w","volume":"7","author":"MMM Almekinders","year":"2021","unstructured":"Almekinders, M. M. M. et al. Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ. npj Breast Cancer 7, 31 (2021).","journal-title":"npj Breast Cancer"},{"key":"453_CR31","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1158\/1078-0432.CCR-15-2239","volume":"22","author":"NM Iyengar","year":"2016","unstructured":"Iyengar, N. M. et al. Systemic correlates of white adipose tissue inflammation in early-stage breast cancer. Clin. Cancer Res. 22, 2283\u20132289 (2016).","journal-title":"Clin. Cancer Res."},{"key":"453_CR32","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3390\/ijms18010232","volume":"18","author":"YJ Cha","year":"2017","unstructured":"Cha, Y. J., Kim, H. M. & Koo, J. S. Expression of lipid metabolism-related proteins differs between invasive lobular carcinoma and invasive ductal carcinoma. Int. J. Mol. Sci. 18, 232 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"453_CR33","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.prp.2016.05.002","volume":"212","author":"M Christgen","year":"2016","unstructured":"Christgen, M. et al. Lobular breast cancer: Clinical, molecular and morphological characteristics. Pathol. Res Pr. 212, 583\u2013597 (2016).","journal-title":"Pathol. Res Pr."},{"key":"453_CR34","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2015.63.9179","volume":"34","author":"P Schmid","year":"2016","unstructured":"Schmid, P. et al. Phase II randomized preoperative window-of-opportunity study of the PI3K inhibitor pictilisib plus anastrozole compared with anastrozole alone in patients with estrogen receptor-positive breast cancer. J. Clin. Oncol. 34, 1987\u20131994 (2016).","journal-title":"J. Clin. Oncol."},{"key":"453_CR35","unstructured":"WHO\/Europe|Nutrition\u2014Body mass index\u2014BMI. http:\/\/www.euro.who.int\/en\/health-topics\/disease-prevention\/nutrition\/a-healthy-lifestyle\/body-mass-index-bmi."},{"key":"453_CR36","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.1200\/JCO.2009.22.4436","volume":"27","author":"M Hyeong-Gon","year":"2009","unstructured":"Hyeong-Gon, M., Wonshik, H. & Dong-Young, N. Underweight and breast cancer recurrence and death: a report from the Korean Breast Cancer Society. J. Clin. Oncol. 27, 5899\u20135905 (2009).","journal-title":"J. Clin. Oncol."},{"key":"453_CR37","unstructured":"R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. R Core Team (2020)."},{"key":"453_CR38","doi-asserted-by":"publisher","first-page":"892","DOI":"10.15626\/MP.2018.892","volume":"3","author":"A Clyburne-Sherin","year":"2019","unstructured":"Clyburne-Sherin, A., Fei, X. & Green, S. A. Computational reproducibility via containers in psychology. Meta-Psychol. 3, 892 (2019).","journal-title":"Meta-Psychol."}],"container-title":["npj Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00453-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00453-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T18:38:17Z","timestamp":1669315097000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41523-022-00453-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["453"],"URL":"https:\/\/doi.org\/10.1038\/s41523-022-00453-7","relation":{},"ISSN":["2374-4677"],"issn-type":[{"value":"2374-4677","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]},"assertion":[{"value":"1 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"G.Z. declares no competing non-financial interests but the following competing financial interests: travel grants from Novartis, Pfizer, and Roche, consultation fees from Novartis, laboratory reagents from Cytiva and ThermoFisher Scientific. All remaining authors declare no competing financial or non-financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"90"}}